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Abstract: Omega-3 long chain polyunsaturated fatty acid (n-3 LCPUFA) supplementation has
been shown to improve plasma lipid profiles in men and post-menopausal women, however,
data for pre-menopausal women are lacking. The benefits of intakes less than 1 g/day have not
been well studied, and dose–response data is limited. The aim of this study was to determine
the effect of low doses of docosahexaenoic acid (DHA)-rich tuna oil on plasma triglyceride (TG)
lowering in pre-menopausal women, and investigate if low dose DHA-rich tuna oil supplementation
would increase the low-density lipoprotein (LDL) and high-density lipoprotein (HDL) particle
sizes. A randomized, double-blind, placebo-controlled trial was conducted, in which 53 healthy
pre-menopausal women with mildly elevated plasma TG levels consumed 0, 0.35, 0.7, or 1 g/day
n-3 LCPUFA as HiDHA™ tuna oil or placebo (Sunola oil) capsules for 8 weeks. Supplementation
with 1 g/day n-3 LCPUFA, but not lower doses, reduced plasma TG by 23% in pre-menopausal
women. This was reflected in a dose-dependent reduction in very-low-density lipoprotein (VLDL)-TG
(R2 = 0.20, p = 0.003). A weak dose-dependent shift in HDL (but not LDL) particle size was
identified (R2 = 0.05, p = 0.04). The results of this study indicate that DHA-rich n-3 LCPUFA
supplementation at a dose of 1 g/day is an effective TG-lowering agent and increases HDL particle
size in pre-menopausal women.
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1. Introduction
The ability of omega-3 long chain polyunsaturated fatty acid (n-3 LCPUFA) to reduce plasma
triglycerides is well established [1,2], and high dose prescriptions of n-3 LCPUFA are commercially
available for treatment of hypertriglyceridemia [3]. High dose n-3 LCPUFA supplementation
may concurrently raise low-density lipoprotein-cholesterol (LDL-C) levels; however, this may be
counteracted by a shift in LDL particle size towards the larger, less atherogenic LDL1 particles [4].
Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) appear to lower plasma triglyceride
(TG) to a similar extent [5], however, DHA seems to be more effective in producing beneficial changes
to LDL and high-density lipoprotein (HDL) particle sizes [5–8]. Yet, while the benefits of higher doses
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(>3 g/day) of n-3 LCPUFA on plasma lipids and lipoproteins are well-established, much less is known
about the benefits of lower doses (<1 g/day). It is important to understand the benefits at these intake
levels, given that they are in the range of recommended dietary intakes.
A dose-dependent lowering of plasma TG (R2 = 0.29) was reported in men and women at moderate
intakes (0–2 g/day) [9], however, the current understanding of dose–response relationships at lower
intakes is limited. Also, the majority of studies have been conducted in men [1] and post-menopausal
women [10–12], who inherently have less favourable HDL-C and HDL2 levels than pre-menopausal
women [13]. Placebo-controlled trials have not been conducted exclusively in pre-menopausal women
to investigate the TG-lowering potential of n-3 LCPUFA. Studies have been conducted in mixed gender
populations [12,14–16], however, the majority have failed to report on sex differences in lipid responses.
Furthermore, sex hormone fluctuations alter blood lipids and lipoproteins [17,18], and the potentially
confounding effects of plasma lipid changes throughout the menstrual cycle have rarely been taken
into account. Research on the TG-lowering effects of n-3 LCPUFA is especially important in women,
given that plasma TGs are a stronger determinant of coronary heart disease (CHD) risk in women than
men [19,20]. Also, while the majority of studies have found no effect of low doses of n-3 LCPUFA on
blood pressure [21], reductions in systolic [22] and diastolic [16] blood pressure have been observed
with just 0.7–1 g/day of DHA or a DHA-rich supplement.
The primary aim of this study was to determine a low dose–response effect of DHA-rich
tuna oil supplementation for plasma TG lowering in pre-menopausal women. Secondary aims
were to determine if the supplementation reduces very-low-density lipoprotein (VLDL)-TG and
intermediate-density lipoprotein (IDL)-TG, increases the larger HDL (HDL2) particles, and increases
LDL particle size from small dense LDL3 to normal-sized LDL particles, in a dose–response manner,
as well as determining whether it lowers blood pressure.
2. Materials and Methods
2.1. Subjects
Healthy premenopausal women with mildly elevated triglycerides (>1.0 mmol/L) and regular
menstrual cycles (28–32 days) were recruited for this study conducted at the University of Wollongong,
Australia. Exclusion criteria included age <18 or >40 years, consumption of fish oil supplements,
and known existing cardiovascular disease (CVD). Subjects who completed the trial were required to
achieve a capsule compliance rate of >90% on the basis of self-report and excess capsule count, and a
body weight change of ≤5% from baseline. Subjects were recruited through advertisement in the local
media (television, radio, newspaper), distribution of fliers in the community, and University email
lists. Of the 269 women who participated in phone screening, 169 were eligible to attend screening
clinic visits (Figure 1). These subjects attended the research clinic for measurement of fasting plasma
TG levels, and their height and weight were recorded for calculation of body mass index (BMI).
Upon exclusion of 93 subjects due to low plasma TGs (<1.0 mmol/L), 76 women were eligible to
participate in the placebo-controlled trial. The study protocol was approved by the Human Research
Ethics Committee of the University of Wollongong, and written informed consent was obtained from
subjects (Australian and New Zealand Clinical Trial Registration ID: ANZCTRN12607000566437).
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contraceptive pill use. n-3 LCPUFA was provided in the form of HiDHA™ tuna oil (500 mg sized 
Figure 1. Flow of participants through the double-blind randomized placebo-controlled trial. TG:
triglyceride; n-3 LCPUFA: omega-3 long chain polyunsaturated fatty acid.
2.2. Study Design
A randomized, double-blind, placebo-controlled trial of parallel design was conducted, whereby
subjects were randomly assigned to consume 0, 0.35, 0.7, or 1.0 g/day of n-3 LCPUFA for two menstrual
cycles (approximately 8 weeks). Randomization was controlled for age, BMI, and contraceptive pill
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use. n-3 LCPUFA was provided in the form of HiDHA™ tuna oil (500 mg sized capsules supplied by
Nu-Mega Ingredients, Australia). Subjects consumed six capsules daily, with the four different doses
achieved by varying the proportion of active (HiDHA™ tuna oil) and placebo (Sunola oil, 500 mg)
capsules for each dose group. Each tuna oil capsule provided 135 mg DHA and 35 mg EPA, whereas
each Sunola capsule provided 355 mg monounsaturated fatty acids (MUFA), 55 mg saturated fatty
acids (SFA), and 14 mg polyunsaturated fatty acids (PUFA) (no n-3 LCPUFA). Daily doses of capsules
were provided in individual zip-lock bags, and an excess of these bags were distributed to subjects.
Subjects also kept a diary to record daily capsule intake and menstrual cycle status. Compliance with
capsule consumption was assessed using the diary records and excess capsule count, and confirmed
by measurement of erythrocyte n-3 LCPUFA levels. Subjects attended the research clinic on two
consecutive mornings each at baseline, and after approximately 8 weeks (two menstrual cycles) of
supplementation. In order to control the confounding effects of the menstrual cycle, the clinic visits
were conducted on days 3–5 of the menstrual cycle, as determined by counting from onset of menses,
and thus were strictly aligned with the onset of menses. This alignment discounts the effect of the
hormonal influence on plasma lipid levels. Subjects were instructed to avoid active weight loss, weight
gain, or dietary changes for the study duration, and to avoid excessive alcohol consumption or physical
activity before all clinic visits.
2.3. Sample Collection and Processing
Following an overnight fast (>10 h), venous blood was collected into ethylenediaminetetraacetic
acid (EDTA) tubes on two consecutive days (36 mL on Day 1; 9 mL on Day 2) at baseline and
post-intervention. Aliquots of plasma and erythrocytes isolated at 4 ◦C were stored at −80 ◦C for
analysis of lipids and fatty acids. Plasma concentrations of TG and cholesterol were measured on each
of the consecutive days at baseline and post-intervention, and the average of these measurements
was used in statistical analyses. Fatty acid and lipoprotein measures were determined at baseline and
post-intervention. Blood pressure was measured in triplicate at all clinic visits using an automatic
blood pressure monitor. Body weight was recorded at baseline and post-intervention. The dietary
macronutrient and micronutrient intakes of subjects were determined using the Victorian Anti-Cancer
Council Food Frequency Questionnaire.
2.4. Clinical Chemistry Methods
Fasting plasma lipid levels (TG and total cholesterol (TC), HDL2, and HDL3 cholesterol) and
isolated lipoprotein components (cholesterol, TG, phospholipids, and apolipoprotein B (apoB)
were measured using an autoanalyser (Konelab 20XT) and commercially available kits, reagents,
and standards from Thermo Electron, USA (cholesterol, TG), Kamiya Biomedical Company, USA
(apoB), and Wako Pure Chemical Industries, Japan (phospholipids). Protein content within lipoproteins
was determined using the Lowry method [23].
2.5. Lipoprotein Analysis
Isolation of lipoprotein fractions was conducted immediately by sequential ultracentrifugation
of fresh plasma (10 mL) adjusted to appropriate densities with potassium bromide. VLDL, IDL,
LDL, and HDL were isolated as the plasma fractions of densities <1.006 g/mL, 1.006–1.030 g/mL,
1.030–1.063 g/mL, and 1.063–1.21, respectively. This was achieved using ultracentrifugation and a
70.1Ti rotor at 39,000 rpm (139,439 g) at 10 ◦C for 16 h at a density of 1.006 g/mL, 18 h at a density
of 1.030 g/mL, and 24 h at densities of 1.063 and 1.21 g/mL. The volumes of VLDL, IDL, LDL,
HDL, and density > 1.21 g/mL samples were recorded to calculate recoveries, and aliquots were
frozen at −80 ◦C for analysis of composition and particle size. The concentration of plasma HDL2
and HDL3 were determined using an established method [13]. Briefly, apoB containing lipoproteins
were precipitated using heparin-manganese followed by enzymatic measurement of the remaining
cholesterol. A second precipitation procedure using dextran sulfate was performed to determine
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the HDL3-C concentration. The concentration of HDL2 was calculated as the difference between the
measured HDL-C and HDL3-C concentrations.
2.6. Lipoprotein Particle Size Analysis
Non-denaturing polyacrylamide gradient gels (Alamo Gels, USA) were used for the separation
of IDL and LDL (2–16% gradient) and HDL subclasses (4–30% gradient) within isolated samples.
Aliquots of IDL (31.5 nm), LDL1 (23.6 nm), and LDL3 (20 nm), for which particle sizes were previously
determined using electron microscopy [24], were also run on the 2–16% gels to generate a standard
curve for the determination of LDL particle size. Standards run on the 4–30% gradient gels included
latex beads (38 nm), thyroglobulin (17.1 nm) ferritin, (12.2 nm), lactate dehydrogenase (8.16 nm),
and albumin (7.1 nm). Following electrophoresis, gels were stained, scanned, and analysed using
Image J version 1.43 u software (National Institutes of Health, Bethesda, MD, USA). Peak particle
diameter was quantified for LDL samples. HDL particle diameter was obtained from a logarithmic
standard curve of the diameter of standards against their positions on the scanned gel. HDL sub-classes
were defined as HDL2b (9.9–12.0 nm), HDL2a (8.8–9.9 nm), HDL3a (8.2–8.8 nm), HDL3b (7.8–8.2 nm),
or HDL3c (7.0–7.8 nm) [25]. For these subclasses, the relative distribution of cholesterol under each
peak was calculated as a percentage of the total area for all HDL subclasses.
2.7. Fatty Acid Analysis
The fatty acid profiles of erythrocytes were determined using standard methods reported
previously [26]. Briefly, erythrocyte aliquots (400 µL) were thawed and re-suspended in a TRIS buffer
(10 mM Bis Tris, 2 mM EDTA Na2, pH 7.2) at room temperature for 30 min. The samples were then
spun in an ultracentrifuge at 315,000 g for 30 min at 4 ◦C (Beckman L-80 OPTIMA, Beckman Coulter,
Burea, CA, USA) to pellet erythrocyte membranes. Upon removal of the supernatant, the erythrocyte
membrane pellet was re-suspended in 200 µL of distilled water. A fixed volume (150 µL) of the
erythrocyte membrane suspension was used for direct transesterification of fatty acids [27] using
heneicosanoic acid as the internal standard. Fatty acid methyl esters (FAMEs) were analysed by
injecting 1 µL of each sample in a gas chromatograph (GC 17A Shimadzu, Shimadzu Corp., Columbia,
MD, USA) equipped with an autoinjector, 30 m FAME capillary column (0.25 mm internal diameter,
Varian, Palo Alto, CA, USA), and flame ionization detector. Hydrogen was used as the carrier gas.
Fatty acid peaks were identified by comparison to known mixed standards (Nu-Chek Prep, Waterville,
MN, USA; Sigma Aldrich, Castle Hill, NSW, Australia), and quantified using Shimadzu software
(Class-VP 7.2.1 SP1, Kyoto, Japan).
2.8. Statistical Analysis
Power calculations were based on the analysis of covariance (ANCOVA) method, as it accounts for
baseline differences while avoiding regression to the mean [28] and has the greatest power for detecting
treatment effects in randomised controlled trial data [28–31]. A sample size formula for analysis of
covariance in randomized controlled trials was used [32], and the total number of participants required
per group was 14. The Shapiro-Wilk test was used to assess whether each variable fit a normal
distribution. All plasma lipid, lipoprotein, and dietary variables were found to be non-normal and
were subsequently transformed using the log10 algorithm prior to statistical analyses.
Baseline differences between dose groups for all parameters were examined using one-way
ANOVA. Comparisons between groups were based on ANCOVA standard least squares models with
Tukey honest significant difference (HSD) analysis. n-3 LCPUFA dose and the baseline value for
each parameter were used as the two covariates in ANCOVA, with the post-intervention value
as the dependent variable. Percentage reductions in parameters were calculated on means of
log-transformed data. For each parameter, a trend test was performed using the n-3 LCPUFA dose
(0, 0.35, 0.7, or 1.0 g/day) as a continuous variable in a multiple regression model (standard least
squares), the baseline value as a covariate, and the post-intervention value as the dependent variable.
Nutrients 2018, 10, 1460 6 of 17
This multiple regression model was used to determine the statistical significance of dose (or baseline
level) as a predictor of the post-intervention measure, as well as the combined predictive capacity of
the two variables. Linear regression was used to determine the individual predictive capacity of each
variable. Statistical analyses were conducted using JMP 5.1 statistical software (SAS, Cary, NC, USA).
3. Results
3.1. Subject Characteristics and Dietary Intake
Of the 64 eligible women who commenced the trial, 56 completed. Drop-outs were due to
time-constraints or unexpected travel (n = 6), surgery (n = 1), and an adverse reaction (mouth ulceration)
that may have been related to capsule consumption (n = 1). Three subjects who completed the trial
were subsequently excluded from analysis (Figure 1). Fifty-three subjects were included in the final
analysis of blood pressure and all lipid and lipoprotein compositions, and 29 were included in analysis
of LDL and HDL particle size. Subject characteristics and nutrient intakes did not significantly differ
between groups (Table 1).
Table 1. Characteristics (values mean ± standard error of the mean (SEM) or median (25th percentile,
75th percentile); n = 53) and daily dietary energy (kJ/day) and macronutrient intakes (g/day) (values
median (25th percentile, 75th percentile); n = 45) of subjects in double-blind placebo-controlled trial
at baseline.
0 g/day (n = 12) 0.35 g/day (n = 15) 0.7 g/day (n = 13) 1 g/day (n = 13) p Value
N 12 15 13 13
OC/Non-OC 6/6 7/8 5/8 7/6
Age (years) 28 ± 2 27 ± 2 24 ± 1 28 ± 2 0.51
BMI (kg/m2) 23 ± 1 26 ± 1 26 ± 2 24 ± 1 0.57
SBP (mm Hg) 116 (108, 120) 117 (107, 121) 115 (110, 125) 110 (105, 112) 0.07
DBP (mm Hg) 69 (65, 75) 70 (68, 80) 70 (65, 82) 69 (66, 72) 0.58
TC (mmol/L) 4.60 (4.02, 5.42) 4.61 (4.13, 4.88) 4.30 (4.14, 4.95) 4.60 (3.90, 5.22) 0.98
Energy (kJ) 6525 (5696, 7475) 5871 (5005, 6888) 6642 (5460, 8081) 5118 (4115, 6365) 0.24
Total Fat (g) 50 (47, 71) 58 (48, 70) 60 (49, 75) 43 (31, 61) 0.44
SFA (g) 24 (20, 29) 23 (18, 28) 24 (20, 30) 18 (12, 25) 0.50
PUFA (g) 7.1 (5.6, 9.0) 8.2 (6.4, 11) 8.6 (6.4, 12) 5.6 (3.6, 8.6) 0.34
MUFA (g) 21 (16, 26) 22 (18, 26) 21 (17, 27) 16 (11, 22) 0.44
Protein (g) 81 (69, 94) 72 (62, 84) 81 (67, 99) 70 (60, 82) 0.44
CHO (g) 179 (162, 197) 148 (126, 174) 177 (142, 221) 136 (113, 164) 0.09
Abbreviations: OC/Non-OC: Oral Contraceptive Use/Non-Use; BMI: Body Mass Index; SBP: Systolic Blood
Pressure; DBP: Diastolic Blood Pressure; TC: Total Cholesterol; SFA: Saturated fatty acids; PUFA: polyunsaturated
fatty acids; MUFA: monounsaturated fatty acids; CHO: Carbohydrate.
3.2. Blood Pressure and Fatty Acids
The study population presented with normal baseline blood pressure, with a trend towards lower
systolic (p = 0.07) but not diastolic (p = 0.58) blood pressure in the 1 g/day group (Table 1). After fish
oil supplementation, both systolic (p = 0.16) and diastolic (p = 0.91) blood pressures were unaffected by
n-3 LCPUFA dose.
Erythrocyte EPA and DHA levels increased in a dose-dependent manner (Figure 2), resulting
in a 15% increase in the Omega-3 Index (erythrocyte EPA + DHA as mol % of total fatty acids) after
0.35 g/day, and increases of 27% and 39% after 0.7 g/day and 1 g/day n-3 LCPUFA, respectively.
3.3. Effect of Dose–Response n-3 LCPUFA Supplementation on Plasma Lipids
The average baseline fasting TG level of the study cohort was 1.23 ± 0.47 mmol/L
(mean ± standard deviation (SD)), with no difference between dose groups (p = 0.56). Individual TG
levels ranged from 0.53–2.42 mmol/L, despite excluding fasting plasma TG levels of >1.0 mmol/L in
the screening phase. BMI was a weak but significant predictor of baseline plasma TG levels (R2 = 0.09,
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p = 0.03). Following 8 weeks of supplementation with 1 g/day n-3 LCPUFA, plasma TG levels
significantly lowered compared to placebo (Table 2). This change amounted to a 23% reduction from
baseline. There was no difference between groups in baseline plasma TC levels (p = 0.98), and no
dose–response effect following n-3 LCPUFA supplementation (p = 0.64). In an intention-to-treat
analysis, plasma TG levels lowered according to increasing dose (R2 = 0.09, p = 0.04) within the
supplemental range of 0–1 g/day n-3 LCPUFA. The dose effect increased upon a per-protocol analysis
(R2 = 0.16, p = 0.003) (Figure 3). When BMI was included in the model in addition to dose and baseline
TG levels, the variability in post-intervention TG levels explained by the model increased slightly, from
R2 = 0.45 to R2 = 0.48.
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with 1 g/day n-3 LCPUFA were significantly lower (32%) than the 0.35 g/day group; however, they were
not significantly lower than placebo due to the apparent VLDL-TG reduction in this group (Table 3).
Lipid components of VLDL reduced in a dose-dependent manner despite no change in VLDL
apoB levels (Table 3), suggesting a reduction in VLDL particle size. As demonstrated by compositional
analysis of all TG-carrying lipoproteins (Tables 3 and 4), the reduction in plasma TG was entirely
due to a reduction in VLDL-TG. Baseline levels were also a predictor of post-intervention plasma TG
and VLDL-TG (Figure 4). When combined with dose in a multiple regression model, plasma TG and
VLDL-TG explained 45% and 33% of the variability in post-intervention levels, respectively (Figure 4).
IDL, LDL, and HDL particle compositions were unaffected by n-3 LCPUFA supplementation
(Table 4). The significant difference between HDL3-C levels in the placebo group and the 0.35 and
0.7 g/day groups was driven by an unexplained increase in the placebo group rather than a reduction
in the treatment groups.
The dominant LDL particle type was LDL2, with small dense LDL3 particles present in very
few subjects and no particle size change upon n-3 LCPUFA supplementation (Table 5). There was a
very weak dose-dependent increase in the proportion of HDL2b particles but not in HDL2a or HDL3a
(Table 5). The change in plasma TG levels was a predictor of the change in the proportion of HDL2b
particles (R2 = 0.15, p = 0.04). Similarly, the change in LDL peak particle size was a predictor of the
change in the proportion of HDL2b (R2 = 0.34, p = 0.0008) (Figure 5), HDL3b (R2 = 0.20, p = 0.01),
and HDL2a (R2 = 0.28, p = 0.003) particles.
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Figure 3. Scatterplot (with linear regression line) of plasma triglyceride levels (mmol/L) following
supplementation with 0, 0.35, 0.7, and 1 g/day n-3 LCPUFA from HiDHA™ tuna oil (n = 53). R2 = 0.16,
p = 0.003 in the per-protocol analysis. 0 g/day group n = 12; 0.35 g/day group n = 15; 0.7 g/day group
n = 13; 1.0 g/day group n = 13.
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Table 3. Changes in VLDL particle composition following supplementation with 0–1 g/day n-3 LCPUFA from HiDHA™ tuna oil (values median (25th percentile, 75th




























TG (mmol/L) 0.81 (0.51, 1.23) 0.60 (0.50, 0.77) 0.72 (0.49, 0.94) 0.66 (0.58, 0.85) 0.96 (0.31, 1.37) 0.51 (0.26, 0.80) 0.50 (0.35, 0.77) 0.35 # (0.22, 0.52) R2 = 0.20, p = 0.003
Chol (mmol/L) 0.36 (0.19, 0.47) 0.19 (0.16, 0.48) 0.31 (0.17, 0.40) 0.24 (0.18, 0.35) 0.30 (0.14, 0.63) 0.19 (0.11, 0.29) 0.21 (0.15, 0.30) 0.16 (0.09, 0.24) R2 = 0.14, p = 0.02
PL (mg/dL) 21 (13, 32) 15 (12, 29) 19 (12, 22) 15 (14, 19) 21 (9, 41) 14 (7, 19) 16 (10, 20) 11 (6, 17) R2 = 0.17, p = 0.003
PR (mg/dL) 14 (10, 17) 12 (10, 15) 18 (12, 21) 12 (9, 17) 15 (9, 22) 11 (9, 14) 10 (9, 15) 11 (8, 13) p = 0.33
TG/PR 5.4 (3.1, 7.5) 5.0 (3.4, 6.6) 3.9 (3.3, 5.5) 6.0 (3.5, 6.7) 4.0 (2.4, 8.1) 3.9 (2.6, 5.3) 4.1 (2.4, 5.4) 2.4 # (2.2, 4.2) R2 = 0.17, p = 0.003
apoB (mmol/L) 6.3 (3.3, 9.0) 5.2 (3.5, 6.2) 7.7 (6.5, 9.6) 5.7 (4.8, 6.5) 5.5 (4.2, 7.2) 4.3 (3.2, 6.6) 5.0 (4.0, 8.0) 4.7 (2.5, 5.5) p = 0.49
TG % 58 (55, 61) 57 (53, 63) 57 (49, 60) 58 (56, 62) 57 (43, 60) 55 (50, 59) 51 (49, 58) 50 # (48, 55) R2 = 0.13, p = 0.02
Chol % 10 (10, 12) 9 (8, 11) 9 (8, 11) 10 (8, 11) 10 (8, 13) 9 (8, 11) 10 (9, 11) 9 (8, 11) p = 0.97
PL % 17 (16, 18) 16 (16, 19) 17 (15, 17) 16 (15, 17) 16 (16, 19) 17 (15, 18) 18 (16, 19) 18 (16, 19) p = 0.82
PR % 11 (8, 18) 12 (9, 17) 14 (11, 17) 10 (9, 16) 15 (7, 19) 15 (11, 21) 14(11, 21) 21 # (13, 23) R2 = 0.16, p = 0.002
Differences between dose groups compared using log-transformed data with ANCOVA followed by post hoc Tukey honest significant difference (HSD) tests. Abbreviations: VLDL: very
low density lipoprotein, TG: triglyceride, Chol: cholesterol, PL: phospholipids; PR: protein, apoB: apolipoprotein B, # Significantly lower than 0.35 g/day using ANCOVA (p < 0.05).
Table 4. Changes in lipoprotein composition following supplementation with 0–1 g/day n-3 LCPUFA from HiDHA™ tuna oil (values median (25th percentile, 75th
percentile); n = 53).
0 g/day (n = 12)
0 weeks
0 g/day (n = 12)
8 weeks
0.35 g/day (n = 15)
0 weeks
0.35 g/day (n = 15)
8 weeks
0.7 g/day (n = 13)
0 weeks
0.7 g/day (n = 13)
8 weeks
1 g/day (n = 13)
0 weeks




IDL-C (mmol/L) 0.33 (0.26, 0.40) 0.37 (0.28, 0.44) 0.37 (0.29, 0.53) 0.35 (0.27, 0.50) 0.37 (0.22, 0.46) 0.30 (0.20, 0.40) 0.36 (0.24, 0.49) 0.41 (0.20, 0.50) p = 0.17
IDL-TG (mmol/L) 0.15 (0.10, 0.17) 0.14 (0.11, 0.16) 0.15 (0.13, 0.19) 0.15 (0.12, 0.17) 0.11 (0.09, 0.14) 0.11 (0.08, 0.12) 0.14 (0.11, 0.17) 0.12 (0.10, 0.18) p = 0.37
IDL-apoB (mmol/L) 10 (7.5, 11) 11 (9.4, 13) 11 (9.7, 12) 11 (7.5, 13) 8.7 (6.7, 11) 7.8 (6.2, 13) 11 (7.5, 15) 14 (7.9, 17) p = 0.65
LDL-C (mmol/L) 2.6 (2.0, 2.8) 2.0 (1.7, 3.0) 2.5 (1.7, 2.8) 2.4 (1.9, 2.8) 2.0 (1.8, 2.3) 2.2 (2.0, 2.5) 2.2 (1.8, 3.1) 2.3 (1.7, 2.8) p = 0.75
LDL-TG (mmol/L) 0.17 (0.11, 0.21) 0.16 (0.13, 0.23) 0.18 (0.15, 0.20) 0.17 (0.15, 0.20) 0.14 (0.11, 0.18) 0.13 (0.11, 0.16) 0.17 (0.14, 0.22) 0.17 (0.14, 0.21) p = 0.64
LDL-apoB (mmol/L) 113 (70.3, 121) 99.5 (61.1, 118) 94.6 (64.3, 118) 115 (75.6, 123) 68.0 (43.9, 98.2) 77.1 (57.4, 120) 107 (77.7, 146) 102 (84.9, 135) p = 0.92
HDL-C (mmol/L) 1.2 (0.94, 1.4) 1.3 (0.98, 1.6) 1.1 (0.89, 1.2) 1.2 (0.96, 1.4) 1.2 (0.94, 1.6) 1.2 (1.0, 1.5) 1.2 (1.0, 1.3) 1.2 (0.99, 1.5) p = 0.26
HDL2-C (mmol/L) 0.59 (0.41, 0.62) 0.59 (0.45, 0.71) 0.49 (0.35, 0.55) 0.56 (0.47, 0.71) 0.61 (0.38, 0.77) 0.65 (0.40, 0.79) 0.54 (0.40, 0.75) 0.66 (0.44, 0.77) p = 0.98
HDL3-C (mmol/L) 0.65 (0.51, 0.79) 0.73 (0.52, 0.83) 0.62 (0.54, 0.68) 0.61 * (0.50, 0.68) 0.63 (0.57, 0.77) 0.60 * (0.55, 0.71) 0.61 (0.52, 0.76) 0.62 (0.49, 0.78) R2 = 0.01, p = 0.04
Abbreviations: IDL: intermediate density lipoprotein, LDL: low density lipoprotein, HDL: high density lipoprotein, TG: triglyceride, C: cholesterol, apoB: apolipoprotein B; * Significantly
lower than 0 g/day using ANCOVA (p < 0.05).
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Table 5. Lipoprotein particle size following supplementation with 0–1 g/day n-3 LCPUFA from HiDHA™ tuna oil (values median (25th percentile, 75th percentile);
n = 29).
0 g/day (n = 12)
0 weeks
0 g/day (n = 12)
8 weeks
0.35 g/day (n =
15)
0 weeks
0.35 g/day (n =
15)
8 weeks
0.7 g/day (n =
13)
0 weeks
0.7 g/day (n =
13)
8 weeks
1 g/day (n = 13)
0 weeks




LDL Radius (nm) 10.9 (10.8, 11.0) 10.9 (10.7, 10.9) 11.0 (10.4, 11.1) 10.9 (10.4, 11.1) 10.9 (10.6, 11.1) 10.7 (10.5, 11.0) 10.9 (10.7, 11.0) 10.8 (10.8, 11.3) p = 0.15
% HDL2b 37 (32, 43) 33 (31, 44) 35 (16, 38) 35 (23, 38) 41 (28, 49) 46 (38, 50) 32 (28, 47) 42 (27, 52) R2 = 0.05, p = 0.04
% HDL2a 30 (27, 33) 28 (26, 37) 24 (22, 31) 25 (22, 31) 26 (21, 35) 26 (21, 32) 31 (22, 33) 31 (24, 33) p = 0.22
% HDL3a 19 (15, 23) 20 (15, 23) 20 (18, 29) 19 (17, 27) 19 (15, 25) 18 (14, 22) 18 (16, 20) 17 (13, 19) p = 0.24
% HDL3b 12 (7, 14) 11 (7, 16) 13 (10, 20) 13 (10, 18) 11 (7, 14) 9 (2, 12) 17 (11, 18) 9 (8, 19) R2 = 0.02, p = 0.07
% HDL3c 0.8 (0.0, 3.3) 0.3 (0.0, 3.9) 6.0 (0.6, 11.5) 6.1 (0.0, 12.5) 1.2 (0.0, 8.2) 1.9 (0.0, 8.2) 1.2 (0.6, 3.0) 0.6 (0.0, 2.1) p = 0.10
Abbreviations: LDL: low density lipoprotein; HDL: high density lipoprotein.
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Figure 5. Scatterplot showing the relationship between the change in LDL particle diameter (nm) and the change in the proportion of HDL2b following supplementation 
with 0, 0.35, 0.7, and 1 g/day n-3 LCPUFA from HiDHA™ tuna oil (n = 29). R2 = 0.34, p = 0.0008. 0 g/day group n = 12; 0.35 g/day group n = 15; 0.7 g/day group n = 13; 1.0 
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Figure 5. Scatterplot showing the relationship between the change in LDL particle diameter (nm) and the change in the proportion of HDL2b following supplementation
with 0, 0.35, 0.7, and 1 g/day n-3 LCPUFA from HiDHA™ tuna oil (n = 29). R2 = 0.34, p = 0.0008. 0 g/day group n = 12; 0.35 g/day group n = 15; 0.7 g/day group
n = 13; 1.0 g/day group n = 13.
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4. Discussion
This was the first double-blind, randomized, placebo-controlled study that assessed the effect of
n-3 LCPUFA supplementation on plasma lipids and lipoproteins in pre-menopausal women where the
confounding effects of the menstrual cycle were strictly controlled. The results revealed that a low
dose of n-3 LCPUFA is effective for lowering plasma and VLDL TG levels in pre-menopausal women.
Supplementation with 1 g/day of n-3 LCPUFA from HiDHA™ tuna oil reduced fasting plasma TG
by 23% compared to placebo. Supplementation with a wide range of DHA doses (0.94–5.7 g/day) in
healthy and hypertriglyceridemic populations have produced remarkably similar reductions in plasma
TG (20–32%) [5–7,9–11,14,15,33–37], suggesting there could be a plateau effect at n-3 LCPUFA doses
greater than 1 g/day. The TG-reduction between 0–1 g/day appeared to be dose-dependent in a linear
fashion, despite the lower doses not significantly lowering TG compared to placebo. These results are
in line with previous reports in mixed gender populations of a lack of TG-lowering with approximately
0.7 g/day of DHA [9,16] or n-3 LCPUFA [38]. Baseline TG levels influenced the TG-lowering effect of
the supplement. This was in agreement with previous reports that individuals with higher baseline TG
levels respond more strongly to supplementation [2]. Substantial inter-individual variability in plasma
TG response was recorded, as noted by others [39,40]. Supplementation with 1 g/day n-3 LCPUFA
produced TG changes ranging from a 49% reduction to a 38% increase from baseline. All other doses
resulted in similarly broad ranges of response. This variability likely contributed to the relatively
weak effect of dose on plasma TG. Hence, research should be conducted in larger study populations to
further elucidate dose–response relationships at low n-3 LCPUFA intakes.
While the protocol strictly controlled for daily variation in TG levels, it is possible there were
uncontrolled factors that were not accounted for. Erythrocyte fatty acid analysis confirmed the
self-report measures that compliance was good, thus the observed variability in TG response is
unlikely due to lack of compliance with capsule consumption. However, similarly to as noted by
others [41], no linear relationship between the change in erythrocyte n-3 LCPUFA levels and the change
in plasma TG was detected. Polymorphisms in the genes for fatty acid translocase (FAT)/CD36 [42],
PPAR-α [43], and apolipoproteins [44,45] are known to contribute to variability in TG response to n-3
LCPUFA supplementation. Apolipoprotein E (apoE) genotype in particular has been studied [46],
however, it appears to have little to no influence on the effect of fish oil in women [47] or on fasting (as
opposed to post-prandial) plasma TG [39,48]. As dietary nutrient intakes were measured only once
rather than at baseline and post-intervention, it is possible that subjects altered their diet during the
study period. Some subjects may also have failed to comply with the fasting protocol or instructions to
avoid alcohol consumption and intense exercise prior to clinic visits.
The mechanisms behind plasma lipid responses to n-3 LCPUFA consumption are not fully
understood, and may differ for EPA and DHA. However, TG reductions appear to be driven by reduced
hepatic VLDL production. SREBP-1c, the hepatic gene transcription factor that regulates endogenous
triglyceride production, is markedly inhibited by n-3 LCPUFA [49,50]. Coupled with increased fatty
acid oxidation by activation of PPAR-α [51], these actions leave less substrate for TG synthesis and
packaging into VLDL. Therefore, as shown in this study, VLDL particles tend to be smaller and less
TG-rich. Moderate-high doses of DHA (2–3 g/day) reduce VLDL particle size [7,34]. Low dose n-3
LCPUFA (0.8 g/day) has also been reported to reduce VLDL lipid, protein, and apoB levels, suggesting
a reduction in particle size and number [52]. However, the latter study was limited by the lack of a
placebo-control, small sample size, and short duration. In the present study, not only was the plasma TG
reduction reflected in a dose-dependent reduction of VLDL-TG levels, their changes were highly related
(R2 = 0.53, p < 0.0001). In contrast, VLDL protein and apoB levels were unchanged, suggesting that the
number of particles secreted by the liver was unaffected. The dose-dependent increase in VLDL-TG
to protein ratio, and changes in their percentages within VLDL particles, also indicates a reduction
in core lipid components but no change in surface constituents. Furthermore, IDL composition did
not change as a result of n-3 LCPUFA supplementation; hence, taken together, these results suggest
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that smaller VLDL particles were secreted as a result of low-dose HiDHA™ tuna oil supplementation,
thereby reducing plasma TG levels, whilst there was no effect on IDL particles.
A reduction in TG substrate for cholesterol ester transfer protein (CETP) limits the exchange
of VLDL TG for cholesterol from HDL and/or LDL, which could lead to the maintenance of larger,
more buoyant LDL and HDL particles. However, in this study HiDHA™ tuna oil had no effect on
LDL composition or particle size in pre-menopausal women. This was not surprising, given that
LDL-C was normal at baseline and small dense LDL particles were not prominent. While other studies
reported no change in LDL-C after supplementation with low doses of n-3 LCPUFA [38,53], DHA
intakes as low as 0.7–1.5 g/day have been shown to increase LDL-C [5,6,9,14,16] and LDL particle
size [6] or cholesterol:apoB ratio [16]. As with plasma TG changes, apoE genotypes appear to alter
LDL response to n-3 LCPUFA supplementation [39], perhaps with DHA but not EPA [48]. However,
Caslake et al. [47] found no genotype-dependent effect with 0.7 or 1.8 g/day, thus suggesting that this
effect may also be dose-dependent. In this study, a very minor dose-dependent change in cholesterol
distribution from the smaller, denser HDL3b and HDL3c particles to the larger, more buoyant HDL2b
particles was observed. More importantly, a positive correlation existed between the increases in
the proportion of HDL2b particles and LDL particle size, suggesting a reduction in CETP-mediated
exchange of triglyceride and cholesterol between lipoproteins in some individuals. The lack of an effect
on total HDL-C was in agreement with the literature, whether low to moderate [9,54] or even high [40]
doses of n-3 LCPUFA were administered. Modest increases in the proportion of HDL2, and reductions
in HDL3, have been reported with as little as 0.7 g/day n-3 LCPUFA [47]. However, males responded
twice as strongly as females [47]; therefore, an effect in premenopausal women was unlikely.
Low dose HiDHA™ tuna oil had no effect on blood pressure in this study population.
While high doses (>3 g/day n-3 LCPUFA) are generally required to reduce blood pressure in
hypertensive patients [21,55], reductions in systolic blood pressure have been demonstrated following
supplementation with low doses (1 g/day n-3 LCPUFA) of both seal oil and HiDHA™ tuna oil [22].
However, the average blood pressure in the aforementioned study was 130/75 mmHg [22]; it is likely
that the comparatively lower baseline blood pressure in this cohort of pre-menopausal women did not
reach the threshold at which n-3 LCPUFA would provide a benefit.
A significant strength of this study was the strict control of confounding effects of the menstrual
cycle on plasma lipids. Indeed, this is the first study to do so and demonstrate the plasma TG-lowering
effect of n-3 LCPUFA in pre-menopausal women. Despite preliminary screening to exclude women
with low plasma TG levels, 16 subjects exhibited baseline plasma TG levels lower than the minimum
for entry to the study. For these participants, there remained little room for further reductions in
TG through HiDHA™ tuna oil supplementation. However, even with this limitation, the percentage
reduction in TG observed in this study after supplementation with 1.0 g/day was similar to reductions
in hypertriglyceridemic subjects and with substantially greater doses of n-3 LCPUFA.
5. Conclusions
Supplementation with 1 g/day HiDHA™ tuna oil is sufficient to lower plasma TG by approximately
20% in pre-menopausal women, and the benefit is of a similar degree to that observed in men and
post-menopausal women. The reduction in plasma TG was not accompanied by an increase in LDL
cholesterol or particle size. There may also be some benefit of HiDHA™ tuna oil to HDL particle
size in premenopausal women. Consumption in this dose range may be of particular significance in
maintaining cardiovascular health in pre-menopausal women, given the greater contribution of TG
levels to their CVD risk.
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